Important pharmacy news and late-breaking industry information updated daily.

On June 15, FDA announced that it has revoked emergency use authorization (EUA) for hydroxychloroquine sulfate and chloroquine phosphate for the treatment of certain hospitalized patients with COVID-19.

FDA announced on Monday that it has revoked the emergency use authorization (EUA) for chloroquine phosphate and hydroxychloroquine sulfate for the treatment of certain hospitalized patients with COVID-19.

Thirteen national pharmacy associations, including APhA, have signed onto a joint statement against racial injustice. The National Pharmaceutical Association (NPhA), the professional organization of pharmacists that is committed to serving the underserved and promoting minorities in pharmacy, led the effort in issuing the joint statement.

CDC released revised vaccination guidance on June 9 that will help pharmacists and other immunization providers administer vaccines to patients during the COVID-19 pandemic. This updated guidance should be viewed along with specific guidance CDC issued for pharmacies last month.

This spring, after the World Health Organization and UNICEF warned that the COVID-19 pandemic could spread swiftly when children gathered for shots, many countries suspended their inoculation programs.

FDA on Thursday approved inebilizumab-cdon (Uplizna—Viela Bio) injection for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults who are anti-aquaporin-4 or AQP4 antibody positive.

The attorneys general of 46 U.S. states, the District of Columbia, and four territories on Wednesday filed suit against 26 drug manufacturers, alleging that the drugmakers conspired to reduce competition and drive up generic drug prices. The lawsuit accuses drug manufacturers of price fixing from at least 2009 through early 2016.

The U.S. government plans to fund and conduct the decisive studies of three experimental coronavirus vaccines starting this summer, according to John Mascola, director of the vaccine research center at the National Institute of Allergy and Infectious Diseases.

New guidance requires laboratories performing COVID-19 testing under a CLIA Certificate of Waiver—including pharmacies enrolled as independent clinical laboratories—to report test results and other data to the U.S. Health and Human Services (HHS) or its designee while the federal public health emergency declaration is in effect. The data will be used to help identify disease incidence and trends and inform mitigation and control activities. While these new reporting requirements add to the administrative costs to testers, it will also help to attribute COVID-19 testing done by pharmacists and pharmacies with CLIA Certificate of Waivers. Testers should begin collecting the data as soon as possible but must begin to do so by August 1, 2020, the data must be submitted daily within 24 hours of receipt of test results.

A peer-reviewed study from the Global Policy Laboratory at the University of California at Berkeley, published Monday in Nature, found that emergency health measures taken in six countries prevented approximately 530 million COVID-19 infections, of which 62 million would probably have been "confirmed cases." Researchers examined the effects